Neuromuscular disorders and anesthesia

Current Opinion in Anaesthesiology

Volumn 14, Issue 6, 2001, Pages 693-698

  Stevens, R D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; AMINOGLYCOSIDE; ANESTHETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA LACTAM ANTIBIOTIC; BRETYLIUM; CALCIUM CHANNEL BLOCKING AGENT; CASPASE INHIBITOR; CHLOROCRESOL; CHOLINESTERASE INHIBITOR; CREATINE; CYCLOOXYGENASE 2 INHIBITOR; DANTROLENE; ENOXIMONE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; IODINATED CONTRAST MEDIUM; LIDOCAINE; MACROLIDE; NEUROTROPHIC FACTOR; PHENOTHIAZINE; PHENYTOIN; PROCAINAMIDE; QUINIDINE; RILUZOLE; SUXAMETHONIUM; TACROLIMUS; UBIDECARENONE; XENON;

ANESTHESIA; BRADYCARDIA; CARDIOPULMONARY HEMODYNAMICS; CARDIOPULMONARY INSUFFICIENCY; DIABETIC NEUROPATHY; DRUG INDUCED DISEASE; DRUG RESPONSE; EATON LAMBERT SYNDROME; GUILLAIN BARRE SYNDROME; HEART ARREST; HUMAN; HYPERKALEMIA; LUNG MECHANICS; MALIGNANT HYPERTHERMIA; MOTOR NEURON DISEASE; MUSCULAR DYSTROPHY; MYASTHENIA GRAVIS; MYOPATHY; NEUROMUSCULAR DISEASE; PATHOGENESIS; PERIOPERATIVE PERIOD; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; THYMECTOMY;

EID: 0035204291     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200112000-00016     Document Type: Review

References (44)

1. Neuromuscular dysfunction in critical illness: What are we dealing with?
2. Amyotrophic lateral sclerosis
3. Neuronal death in amyotrophic lateral sclerosis is apoptosis: Possible contribution of a programmed cell death mechanism
4. Amyotrophic lateral sclerosis: Unfolding the toxicity of the misfolded
5. Current treatment of neuromuscular disease
6. Neurological diseases
7. Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation
8. Preceding infection, immune factors and outcome in Guillain-Barré syndrome
9. Pathogenesis of Guillain-Barré syndrome
10. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system
11. Randomized controlled trial of brain derived neuroptrophic factor in Guillain-Barré syndrome: A pilot study
12. Reversal of experimental diabetic neuropathy by VEGF gene transfer
13. Efficacy and safety of human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial
14. Peripheral neuropathy treatment trials
15. Evaluation of standard haemodynamic tests of autonomic function and HbA1c as predictors of delayed gastric emptying in patients with type 1 diabetes mellitus
16. Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature
17. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies
18. Myasthenia gravis: A clinical trials perpective
19. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology
20. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice
21. Muscle diseases
22. Perioperative medical management and outcome following thymectomy for myasthenia gravis
23. Preanesthetic train-of-four fade predicts atracurium requirement of myasthenia gravis patients
24. Neuromuscular monitoring at the orbicularis oculi may overestimate the blockade in myasthenic patients
25. Molecular targets for autoimmune and genetic disorders of neuromuscular transmission
26. Incidence of malignant disease in biopsy-proven inflammatory myopathy
27. Deconstructing myotonic dystrophy
28. Clinical trials in muscle disorders
29. Anesthetic and surgical complications in 219 cases of myotonic dystrophy
30. Anaesthesia and myotonia: An Australian experience
31. Continuous propofol anesthesia for patients with myotonic dystrophy
32. The neurobiology of Duchenne muscular dystrophy: Learning lessons from muscle?
33. Myogenic stem cells for the therapy of primary myopathies: Wishful thinking or therapeutic perspective?
34. Anesthetic complications. The incidence of severe anesthetic complications in patients and families with progressive muscular dystrophy of the Duchenne and Becker types
35. Malignant hyperthermia: Advances in clinical management and diagnosis
36. Xenon does not produce contracture in human malignant hyperthermia muscle
37. 2+ release from skeletal muscle sarcoplasmic reticulum
38. 2+ release
39. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis
40. A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility
41. Effect of the phosphodiesterase III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible individuals
42. Hypersensitivity of malignant hyperthermia-susceptible swine skeletal muscle to caffeine is mediated by high resting myoplasmic [Ca2+]
43. Apoptosis in the nervous system
44. Stem cells and pattern formation in the nervous system: The possible versus the actual